VERIGRAFT has received a grant through the EU Horizon Europe Framework Program for participation in the TELEGRAFT project. Together with six other partners in the consortium, the project aims to generate an arteriovenous graft (AVG) that is puncture safe, anti-thrombotic, has drug releasing abilities, and is equipped with sensors for remote monitoring of blood pressure, blood flow, tissue integrity, and infection. Over 10% of the population worldwide is affected by chronic kidney disease and most of the patients are relying on hemodialysis to survive. 70% of the arteriovenous grafts currently used for hemodialysis fail within a year due to occlusion, thrombosis, or infection. The TELEGRAFT AVG will be a more advanced and reliable alternative to the AVGs currently available for hemodialysis. Total grant amount 4 352 522.00 Euro.
For more information, visit the TELEGRAFT project web page:
Gothenburg, Sweden October 2022 – VERIGRAFT announced today that Petter Björquist, CEO will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, California and livestreamed globally.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 90 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.
The following are specific details regarding VERIGRAFT’s presentation at the conference:
Event: 2022 Cell & Gene Meeting on the Mesa
Date: Oct 12, 2022
Time: 4:00 PM in the Oxford Biomedica Ballroom
Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011
Virtual attendance is available which includes a livestream of VERIGRAFT’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemesa.com for full information including registration.
Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at email@example.com and interested media should contact Stephen Majors at firstname.lastname@example.org.